Morningstar

Damien Conover, CFA

Damien Conover, CFA, is director of equity research, North America, for Morningstar.

More From Damien Conover

Mixed phase 2 data for Rova-T has rocked the narrow-moat firm's stock price, but the data doesn't end the potential of the drug, only likely delays its pathway to approval.
Damien Conover, CFA

The wide-moat drugmaker's cardiovascular drug, Praluent, which it has developed with Regeneron, enjoyed favorable results in a study.
Damien Conover, CFA

The overpayment to enter the increasingly competitive hemophilia market is relatively small compared with the overall size of wide-moat Sanofi.8445
Damien Conover, CFA

Strong top-line Keytruda data reinforces the wide-moat pharma's first mover-advantage in the United States and will help launch the drug in Europe.
Damien Conover, CFA

Better standards align manager incentives with shareholder interests.
Damien Conover, CFA

More About Damien Conover

Damien Conover, CFA, is director of equity research, North America, for Morningstar*.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center